SRC and glioblastoma: Low, non-toxic concentrations of dasatinib, a Src inhibitor, significantly affected the migration and diffusive properties of EGFRwt cells induced by EGFRvIII cells, as well as of GBM cellular populations comprised of both EGFRwt and EGFRvIII subpopulations.